Inflammopharmacology. 2022. Epub ahead of print doi: 10.1007/s10787-022-00936-w
This study of the effectiveness of JAKinibs or abatacept in patients with RA-interstitial lung disease (RA-ILD) shows that treatment is related to stability or improvement of RA-ILD in over 80% of patients.
Often associated with a worse prognosis and mortality, pulmonary involvement in RA has been the subject of increasing interest in recent years, with RA-ILD occurring in up to 67% of patients. However, little information and limited clinical data can make the treatment and management of RA-ILD a challenge.
To help address this, Tardella, et al. used data extracted from a database dedicated to RA patients referred to the Rheumatology Clinic, Università Politecnica delle Marche in Italy, to evaluate the evolution of pulmonary fibrosis in patients receiving JAKinibs compared to those receiving abatacept.